Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00351975
Status:
COMPLETED
Last Update Posted:
2014-12-23
First Post:
2006-07-13
Brief Title:
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Secondary Myelodysplastic Syndrome |
| Accelerated Phase of Disease |
| Adult Acute Myeloid Leukemia With Inv16p131q22 CBFB-MYH11 |
| Adult Acute Myeloid Leukemia With t1616p131q22 CBFB-MYH11 |
| Adult Acute Myeloid Leukemia With t821q22q22 RUNX1-RUNX1T1 |
| Adult Acute Myeloid Leukemia With t911p22q23 MLLT3-MLL |
| Adult Acute Promyelocytic Leukemia With t1517q22q12 PML-RARA |
| Atypical Chronic Myeloid Leukemia BCR-ABL1 Negative |
| Blastic Phase |
| Chronic Myelogenous Leukemia BCR-ABL1 Positive |
| Chronic Myelomonocytic Leukemia |
| de Novo Myelodysplastic Syndrome |
| MyelodysplasticMyeloproliferative Neoplasm Unclassifiable |
| Philadelphia Chromosome Negative BCR-ABL1 Positive Chronic Myelogenous Leukemia |
| Previously Treated Myelodysplastic Syndrome |
| Primary Myelofibrosis |
| Recurrent Adult Acute Lymphoblastic Leukemia |
| Recurrent Adult Acute Myeloid Leukemia |
| Recurrent Disease |
| Secondary Acute Myeloid Leukemia |
Keywords: